Nerve Agents (“Nerve Gas”)

Overview and Pathophysiology

Definition and Agent Families

Nerve agents are highly toxic organophosphorus chemical warfare agents that inhibit AChE, producing an acute cholinergic crisis.^1,2

• The term “nerve gas” is a misnomer: most agents are liquids that can volatilize and be inhaled as vapor or aerosol.^1,2
• Major agent families include G-series (e.g., tabun, sarin, soman, cyclosarin), which are relatively volatile and “nonpersistent,” and V-series (e.g., VX), which are less volatile, more persistent, and pose a major dermal hazard.³
• “A-series”/Novichok agents (often called fourth-generation agents) include compounds with variable physical forms (liquid/solid) and may “age” rapidly, limiting oxime effectiveness.^4,5

Mechanism, Toxidrome, and the Concept of Aging

• AChE inhibition increases acetylcholine at muscarinic, nicotinic, and central nervous system synapses, causing secretory, bronchial, neuromuscular, and neurologic toxicity.^1-3
• After phosphorylation, some agents undergo “aging” (a conformational change that makes AChE reactivation by oximes ineffective). The aging rate varies by agent (minutes for soman; hours for sarin; up to ~24 hours for VX), so early oxime administration is emphasized when significant exposure is suspected.⁶

Why This Matters to Anesthesiology

• Life-threatening effects are respiratory: bronchorrhea/bronchospasm, central respiratory depression, and neuromuscular paralysis. Early airway control and ventilatory support may be required.^1,2
• Patients may present with combined traumatic injury and nerve agent intoxication (e.g., terrorism or battlefield settings), creating competing priorities for resuscitation, decontamination, and urgent surgery.⁷

Clinical Presentation, Diagnosis, and Decontamination

Clinical Presentation

Clinical effects reflect excess acetylcholine at muscarinic, nicotinic, and central synapses; symptom onset depends on dose, agent volatility, and route of exposure.^1-3,6

• Vapor exposure typically causes rapid rhinorrhea, bronchospasm/bronchorrhea, cough, chest tightness, miosis, and dyspnea; severe exposure may rapidly progress to seizures, apnea, and flaccid paralysis.³
• Dermal exposure (particularly with persistent agents such as VX) may present with localized diaphoresis, fasciculations, nausea, and weakness before evolving to systemic toxicity.³
• Classic bedside pattern: “wet” findings (salivation, lacrimation, sweating, bronchorrhea), gastrointestinal hypermotility, bradycardia or hypotension, miosis, and neuromuscular fasciculations progressing to weakness.⁶

Diagnosis and Monitoring

• Diagnosis is clinical. Treatment should not be delayed for laboratory confirmation in a suspected exposure with compatible toxidrome.^3,6
• Cholinesterase activity (red blood cell AChE and/or plasma butyrylcholinesterase) can support exposure assessment and trend recovery, but results may not be immediately available.³
• Continuous monitoring should include pulse oximetry, capnography (if intubated), frequent airway suctioning as needed, hemodynamics, temperature, and neuromuscular function (e.g., train-of-four) when paralysis is present or neuromuscular blocking agents are used.¹

Decontamination and Staff Safety

Secondary contamination is most concerning after liquid/persistent agent exposure. When feasible, decontamination should occur before entry to enclosed care areas (emergency department, operating room, intensive care unit [ICU]).^3,8

• The patient should be removed from the exposure source; all clothing and personal items should be removed (often eliminating most external contamination) and double-bagged.^3,8
• Eyes should be irrigated with copious water or saline if ocular exposure is suspected.^3,8
• Exposed skin and hair should be washed with soap and water; vigorous scrubbing should be avoided. Reactive Skin Decontamination Lotion or dilute hypochlorite solutions may be used per institutional protocols when available, followed by thorough rinsing.^6,8
• Appropriate personal protective equipment (PPE) and facility zoning (hot/warm/cold) should be ensured for staff, and HazMat/chemical response teams should be notified early.⁸

Triage and Disposition

• Patients with significant respiratory symptoms, altered mental status, seizures, or weakness require immediate antidotal therapy, airway management, and critical care admission.^1-3,8
• After decontamination and stabilization, ongoing atropine requirements, recurrent bronchospasm/secretions, and delayed neuromuscular weakness may necessitate prolonged observation and ventilatory support.^1-3,6

Treatment and Anesthetic Considerations

Immediate Priorities

• Standard resuscitation priorities (airway, breathing, circulation) should be followed while decontamination and staff protection are coordinated; airway management may need to occur before complete decontamination in life-threatening exposures.^1-3,8
• High-flow oxygen should be provided, suctioning should be performed aggressively, and early ventilatory support should be instituted for bronchorrhea/bronchospasm and neuromuscular weakness; rapid deterioration should be anticipated after high-dose vapor exposure.^1-3
• Seizures should be treated promptly and repeatedly; ongoing seizure activity worsens hypoxia, acidosis, and neurologic injury.^1,2,6

Antidotal Therapy

Antidotes should be guided by clinical response rather than a fixed total dose. The most important endpoint is improved ventilation with drying of bronchial secretions.^1-3,8

• Atropine (muscarinic antagonist) should be repeated every 5–10 minutes as needed until secretions begin to dry and ventilation improves; tachycardia is not a therapeutic endpoint.^3,8
• 2-PAM or another oxime should be administered early for significant weakness, fasciculations, or respiratory failure to reverse nicotinic effects; benefit decreases after agent-specific aging.^1-3
• Benzodiazepines (e.g., diazepam or midazolam) are first-line therapy for seizures and may be used for agitation or to facilitate ventilation.^1,2,6

Airway Management and Neuromuscular Blockade

• Difficult ventilation from copious secretions and bronchospasm should be anticipated; frequent suctioning and high inspired oxygen are often required during induction and transport.^1-3
• Succinylcholine and mivacurium should be avoided when possible: depressed plasma cholinesterase activity after exposure can prolong paralysis and delay neurologic assessment.^1,2,6
• If rapid-sequence intubation is required, a nondepolarizing neuromuscular blocking agent (e.g., rocuronium) may be used; depth of blockade should be monitored with quantitative train-of-four monitoring.^1,2
• Neostigmine/glycopyrrolate should be avoided for reversal when alternative options exist, because additional AChE inhibition can theoretically worsen cholinergic features; sugammadex may be preferred for aminosteroid blockade.^1,9

Operating Room and ICU Considerations

• Decontamination status should be confirmed prior to entry to the operating room. If contamination is possible, facility chemical incident protocols should be followed (designated decontamination area, restricted traffic flow, appropriate PPE, and waste containment).^7,8
• Closed-suction systems should be used, and aerosol-generating procedures should be minimized when feasible; negative-pressure rooms may be considered for ongoing respiratory failure, if available.^7,8
• Antidotes and supportive care should be continued intraoperatively. For ongoing bronchorrhea/bronchospasm, atropine titration should be guided by ventilation rather than heart rate.^1-3,8
• Prolonged mechanical ventilation should be anticipated in severe exposures. Sedation and analgesia should be titrated to facilitate ventilation and seizure control; intensive care admission is often required even after initial stabilization.^1,2,6

Special Populations

• Pregnancy: atropine, 2-PAM, and benzodiazepines may be used when clinically indicated; maternal stabilization takes priority. Fetal monitoring should be considered once the mother is stabilized.^3,8
• Pediatrics: weight-based dosing and age-appropriate autoinjectors are used when available; early airway support is often required because small airway caliber amplifies the impact of secretions and bronchospasm.^3,6,8

Complications and Follow-up

• Recurrent bronchospasm/secretions and delayed neuromuscular weakness can occur after initial improvement; ongoing reassessment is essential.^1,2,6
• Neurocognitive, psychiatric, and sleep symptoms have been described after severe exposures; arrange follow-up when clinically relevant.⁶